![Molecular imaging of aortic endothelial phenotype in wild-type and ApoE−− mice. (A) Mean (± standard error of the mean [SEM]) signal enhancement measured from the proximal thoracic aorta on CEU molecular imaging using tracers targeted to platelet GPIbα, VWF A1-binding domain, or control agent, in wild-type mice treated for 1 week with ponatinib (30 mg/kg per day), dasatinib (20 mg/kg per day), or vehicle. *P < .01. (B) Illustrative images from a ponatinib-treated wild-type mouse showing 2-dimensional (2-D) ultrasound (14 MHz) of the proximal thoracic aorta and origin of the brachiocephalic artery (outlined), and background-subtracted color-coded (scales at right) CEU molecular imaging with control or targeted contrast agents. (C) Mean (± SEM) signal enhancement on CEU molecular imaging of the proximal thoracic aorta in ApoE−/− mice on a WSD treated for 1 week with ponatinib (30 mg/kg per day) or vehicle. *P < .05. (D) CEU molecular imaging in ponatinib-treated ApoE−/− mice on a WSD showing effects of either daily coadministration of NAC (600 mg/kg per day) or IV rADAMTS13 (5 μg) given 1 hour prior to imaging. *P < .05; **P < .01. IU, international unit.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/133/14/10.1182_blood-2018-10-881557/4/blood881557f2.png?Expires=1720795412&Signature=mt1VaHSWF7E7EdqDaYaZvATXgvDbhkalM2IZl8t4nVFfWc1UMNI-~gNnWNC0KIyjPusjuRyKEzNWrYmgh7aH3hVfa~tADULMchcrBci1gSFTqAe9CQ0vXAGAZS1f0ARdOZ6rrBelERjALzbc~nhm1uYpLDaIKs8dBP592xGRysL~kep5D-LdZGcr7q~JLtb9DTjzwBMoGO04wkSE1tmL3wdhkuf0Sf9ncKtzMmfDCUT52riQbdJAw73PGciJU~Zoo-I5nVHoXGS2BLyGbf8Attph5UYioAcQUG5rBKsVOGFl~1kbnIeMefApIo62CJEiN51c~4JXMnS8b7-QltXqzA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Molecular imaging of aortic endothelial phenotype in wild-type and ApoE−− mice. (A) Mean (± standard error of the mean [SEM]) signal enhancement measured from the proximal thoracic aorta on CEU molecular imaging using tracers targeted to platelet GPIbα, VWF A1-binding domain, or control agent, in wild-type mice treated for 1 week with ponatinib (30 mg/kg per day), dasatinib (20 mg/kg per day), or vehicle. *P < .01. (B) Illustrative images from a ponatinib-treated wild-type mouse showing 2-dimensional (2-D) ultrasound (14 MHz) of the proximal thoracic aorta and origin of the brachiocephalic artery (outlined), and background-subtracted color-coded (scales at right) CEU molecular imaging with control or targeted contrast agents. (C) Mean (± SEM) signal enhancement on CEU molecular imaging of the proximal thoracic aorta in ApoE−/− mice on a WSD treated for 1 week with ponatinib (30 mg/kg per day) or vehicle. *P < .05. (D) CEU molecular imaging in ponatinib-treated ApoE−/− mice on a WSD showing effects of either daily coadministration of NAC (600 mg/kg per day) or IV rADAMTS13 (5 μg) given 1 hour prior to imaging. *P < .05; **P < .01. IU, international unit.